Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Research analysts at B. Riley boosted their Q1 2025 EPS estimates for Eton Pharmaceuticals in a note issued to investors on Wednesday, March 19th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings per share of $0.06 for the quarter, up from their previous forecast of $0.03. B. Riley currently has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' Q2 2025 earnings at $0.00 EPS.
Several other equities analysts have also weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $33.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, March 19th.
Read Our Latest Report on ETON
Eton Pharmaceuticals Price Performance
NASDAQ:ETON traded up $0.57 during trading hours on Thursday, reaching $14.79. The company had a trading volume of 222,236 shares, compared to its average volume of 160,068. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41. The business's 50 day moving average price is $15.59 and its 200-day moving average price is $11.71. The firm has a market cap of $396.64 million, a PE ratio of -67.23 and a beta of 1.37.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). The business had revenue of $11.65 million during the quarter, compared to analysts' expectations of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in ETON. Nantahala Capital Management LLC raised its position in Eton Pharmaceuticals by 12.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company's stock worth $14,898,000 after acquiring an additional 119,750 shares during the period. Westside Investment Management Inc. increased its stake in shares of Eton Pharmaceuticals by 5.7% during the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company's stock worth $3,711,000 after purchasing an additional 33,275 shares in the last quarter. Mink Brook Asset Management LLC acquired a new position in shares of Eton Pharmaceuticals during the 4th quarter worth about $6,071,000. Cannell Capital LLC acquired a new position in shares of Eton Pharmaceuticals during the 4th quarter worth about $5,079,000. Finally, Parkman Healthcare Partners LLC lifted its stake in Eton Pharmaceuticals by 6.4% in the 4th quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company's stock valued at $3,688,000 after buying an additional 16,664 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company's stock.
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Read More
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
